Cover Image
市場調查報告書

生物銀行:技術和全球市場

Biobanking: Technologies and Global Markets

出版商 BCC Research 商品編碼 204227
出版日期 內容資訊 英文 163 Pages
訂單完成後即時交付
價格
Back to Top
生物銀行:技術和全球市場 Biobanking: Technologies and Global Markets
出版日期: 2016年11月30日 內容資訊: 英文 163 Pages
簡介

全球生物銀行技術市場,預計從2016年的1,982億美元,擴大到2021年的2,402億美元。預計市場2016年∼2021年以3.9%的年複合成長率成長。

本報告提供全球生物銀行市場相關調查分析,概要,市場趨勢與預測,市場明細,新產品開發,主要企業等相關的系統性資訊。

第1章 簡介

第2章 摘要

第3章 概要

  • 產業現狀
  • 生物銀行的流程
  • 歷史背景
  • 生物銀行促進成長的要素
  • 生物銀行阻礙成長的要素
  • 生物銀行的趨勢與預測
  • 未來的生物醫學開發藥劑中生物銀行所扮演的角色

第4章 生物銀行應用概要

  • 生物標記
  • 癌症的機會
  • 心血管疾病的機會
  • 神經疾病的機會
  • 免疫學的機會
  • 其他生物銀行的機會

第5章 全球生物銀行現況

  • 概要
  • 美國的生物銀行
  • 歐洲的生物銀行
  • 其他地區的生物銀行

第6章 疾病為基礎的生物銀行

  • 疾病為基礎的生物銀行的成長
  • 癌症生物銀行
  • 健康標本生物銀行
  • 聯盟網路

第7章 人口為基礎的生物銀行

  • 簡介
  • 人口為基礎的生物銀行的種類
  • 世代研究
  • 人口為基礎的生物銀行的成立者
  • 國家的人口為基礎的生物銀行

第8章 營利目的生物銀行企業

  • 委託生物銀行與服務提供者
  • 生物標記藥物研發企業
  • 醫藥品收集
  • 研究聯盟
  • 臨床試驗

第9章 生物銀行的限制

  • 標本的變動性
  • 標本的品質
  • 提高調整性的努力
  • 生物銀行改善的配合措施

第10章 法規趨勢,智慧財產權,倫理的考察

  • 簡介
  • FDA所扮演的角色
  • 法律規範現況
  • 得到說明並且同意
  • 脫離與擁有
  • 機密保持
  • 商業化
  • 對生物標記應用的FDA指南
  • 歐洲藥品管理局 (EMA)
  • 智慧財產權與競爭定位
  • 道德考察
  • 法規關係

第11章 生物銀行市場預測:市場區隔、各地區

  • 摘要
  • 各地區結構

第12章 生物標記利用概要

  • 大腸癌症
  • 乳癌
  • 肺癌症
  • 前列腺癌症
  • 卵巢癌症
  • 心血管系統
  • 中樞神經系統
  • 自體免疫疾病
  • 免疫學

第13章 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BIO084B

The global market for biobanking technologies was valued at $186.3 billion in 2015. This market is expected to increase from $198.2 billion in 2016 to $240.2 billion in 2021 at a compound annual growth rate (CAGR) of 3.9% for 2016-2021.

This report provides:

  • An overview of the global markets for biobanking, the storage of biological samples for the future.
  • Analyses of global market trends, with data from 2015, estimates for 2016 and projections of compound annual growth rates (CAGRs) through 2021.
  • Detailed analyses of how biobanks can lead to new products for specific diseases to overall industry trends.
  • Breakdowns of the biobanking market by product, disease category, and geographic region or country.
  • New products approved by the FDA, and those products expected to be approved within the forecast period.
  • Analysis of the leading competitors, as well as emerging companies in the current worldwide biobanking market.
  • Profiles of the manufacturers of leading products, and their specific product strategies are outlined.

image1

REPORT SCOPE

SCOPE OF REPORT

This report entails forecasted and prevailing biobank products within the 2016 to 2021 period. Biobanks play a critical role in the development of new drugs. The document also features new FDA-approved products in 2015 and 2016, as well as those awaiting approval within the forecast period. The 2016 figures in this report are approximated except in cases where reports of exact results have been released; this is attributed to the timing of this report's release.

Emerging companies and the leading competitors in the prevailing global Biobanks industry are analyzed extensively in this report. The specific product strategies and products of leading drug manufacturers in the market are analyzed and profiled in the report. Biotechnology companies that utilize biobanks to develop new, novel products are also included in the analysis. New products expected to be introduced in the market within the forecast period and their manufacturers, in addition to their impact on the competitive biobank market are discussed in this report. The competitive market environment is evaluated with a unique emphasis on the effect of the new technologies and products on the prevailing patient care standard. Emerging companies and current leaders in the market are profiled and discussed in detail.

Market figures are founded on the revenue level of the manufacturers and forecast done in the 2016-dollar value. Forecast figures exclude inflation. Parameters like the introduction of new products, forecast sales for prevailing products, expanded indications for prevailing products and forecasted changes in the rates of diagnosis, prevalence and scripting for specific diseases are considered when assessing trends.

Forecasts featured in this report for the period between 2016 and 2021 are based on disease category, product and company. The study is organized for an overview of the biobanks market by geography, company and product. The projections are based on country or geographic region. For every disease sub-segment, the global market is evaluated and data provided.

Consumables that do not require prescription from a physician like over-the-counter (OTC) drugs are not covered in this report.

Sales figures are in U.S. dollars, with each reflecting change in revenue performance due to currency fluctuations. Variations in local currencies, however, are not accounted for by the revenue figures.

Unless pointed out, all data on market share in the report are on a global basis.

ANALYST'S CREDENTIALS

Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy, where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • ANALYST'S CREDENTIALS
  • METHODOLOGY AND INFORMATION SOURCES
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • SUMMARY TABLE GLOBAL MARKET FOR BIOBANKS BY SEGMENT, THROUGH 2021 ($ BILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET FOR BIOBANKS BY SEGMENT, 2015-2021 ($ BILLIONS)

CHAPTER 3 OVERVIEW

  • CURRENT STATE OF THE INDUSTRY
  • THE PROCESS OF BIOBANKING
  • HISTORICAL CONTEXT
    • SCIENTIFIC AND COMMERCIAL RELEVANCE OF BIOBANKS
    • TABLE 1 CUMULATIVE NUMBER OF DNA SAMPLES BANKED IN POPULATION-BASED STUDIES*, 1970-2015
    • TABLE 2 VALUE OF DNA SAMPLES STORED, THROUGH 2021
    • TABLE 3 NIH SPONSORED CLINICAL TRIALS CONDUCTING GENE EXPRESSION PROFILING, 2000-2014* (CUMULATIVE NUMBER OF NIH -SPONSORED CLINICAL TRIALS)
      • Modern Biobanks
    • BIOBANKING COSTS
  • DRIVERS OF BIOBANKS GROWTH
  • RESISTORS OF BIOBANKS GROWTH
  • BIOBANKING TRENDS AND FORECAST
  • THE ROLE OF BIOBANKS IN FUTURE BIOMEDICAL DISCOVERIES

CHAPTER 4 OVERVIEW OF BIOBANK APPLICATIONS

  • TABLE 4 GLOBAL MARKET FOR BIOBANKING BY APPLICATION, THROUGH 2021 ($ MILLIONS)
  • BIOMARKERS
  • TABLE 5 SELECTED CANCER BIOBANKS IN THE U.S.
  • TABLE 6 GLOBAL MARKET FOR BIOMARKERS IN LATE STAGE CLINICAL USE BY THERAPEUTIC AREA, THROUGH 2021 ($ MILLIONS/%)
  • OPPORTUNITIES IN CANCER
  • TABLE 7 APPLICATION OF BIOBANKS IN CANCER TREATMENT
  • TABLE 8 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: ONCOLOGY
  • OPPORTUNITIES IN CARDIOVASCULAR DISEASE
  • TABLE 9 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CARDIOVASCULAR
  • OPPORTUNITIES IN NEUROLOGICAL DISEASES
    • THE BRAIN AND THE CENTRAL NERVOUS SYSTEM
    • TABLE 10 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE
  • OPPORTUNITIES IN IMMUNOLOGY
    • AUTOIMMUNE DISEASES
    • TABLE 11 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: IMMUNOLOGY
    • SYSTEMIC LUPUS ERYTHEMATOSUS
    • ALZHEIMER'S DISEASE
  • OTHER OPPORTUNITIES RESULTING FROM BIOBANKS
    • TARGETED THERAPEUTICS
    • DIAGNOSTIC AND PROGNOSTIC TESTS
      • Diagnostic Tests
      • Prognostic Tests
    • DRUG DEVELOPMENT
    • DISEASE ETIOLOGY

CHAPTER 5 CURRENT BIOBANKS WORLDWIDE

  • OVERVIEW
  • TABLE 12 GLOBAL MAJOR BIOBANKS LOCATIONS, BY COUNTRY, 1998-2009
  • TABLE 13 TYPES OF BIOBANKS
  • U.S. BIOBANKS
  • TABLE 14 MAJOR NHLBI COHORT STUDIES
  • TABLE 15 EXAMPLES OF MAJOR DISEASE-BASED BIOBANKS
  • EUROPEAN BIOBANKS
    • THE UNITED KINGDOM
      • UK Biobank
      • Licensed Biobanks in The U.K.
      • TABLE 16 ESTABLISHMENTS LICENSED TO OPERATE BIOBANKS IN THE U.K., 2016
      • TABLE 17 FUNDING SOURCES FOR BIOBANKS LICENSED IN THE U.K. (%)
      • Biobank and Biomolecular Resource Research Infrastructure
      • TABLE 18 COMPOSITE FUNDING METHODS FOR BIOBANKS IN BBMRI COUNTRIES (%)
      • TABLE 19 DISTRIBUTION OF BIOBANKS IN EU COUNTRIES
      • TABLE 20 OWNERSHIP OF EUROPEAN BIOBANKS (%)
      • TABLE 21 ACCESS TO THE EUROPEAN BIOBANK (%)
    • BIOBANKS IN NORTHERN EUROPE
      • Biobanks in Denmark
      • Biobanks in the Baltic Countries
    • INTERNATIONAL BIOBANKS IN OTHER PARTS OF THE WORLD
      • Canadian Partnership for Tomorrow Project
      • Far East Biobanks
      • China Biobank
      • The Qatar Biobank
      • Middle East Biobanks

CHAPTER 6 DISEASE-BASED BIOBANKS

  • GROWTH IN DISEASE-BASED BIOBANKS
  • TABLE 22 GROWTH IN DISEASE-BASED BIOBANKS BY THERAPY IN THE U.S., 2007-2014
  • CANCER BIOBANKS
  • BIOBANKS FOR OTHER DISEASES
  • HEALTHY SAMPLE BIOBANKS
  • COLLABORATIVE NETWORKS
    • CORE UK
    • INTERNATIONAL GENOMICS CONSORTIUM
    • CANCER GENOME ATLAS
    • SEGMENT FORECAST

CHAPTER 7 POPULATION BASED BIOBANKS

  • INTRODUCTION
  • TYPES OF POPULATION BIOBANKS
  • COHORT STUDIES
  • TABLE 23 SELECTED POPULATION-BASED COHORT BIOBANKS, 1976-2009
  • FOUNDER POPULATION BIOBANKS
  • TABLE 24 FOUNDER POPULATION-BASED BIOBANKS
    • DECODE GENETICS
    • CARTAGENE
    • GENIZON BIOSCIENCES
    • JURILAB
  • NATIONAL POPULATION BIOBANKS
    • UK BIOBANK
    • LIFEGENE
    • ESTONIAN BIOBANK
    • LATVIAN BIOBANK
    • CANADIAN PARTNERSHIP FOR TOMORROW PROJECT
    • OTHER NATIONAL BIOBANKS

CHAPTER 8 FOR-PROFIT BIOBANK COMPANIES

  • CONTRACT BIOBANK AND SERVICE PROVIDERS
  • BIOMARKER DISCOVERY COMPANIES
  • PHARMACEUTICAL COLLECTIONS
  • RESEARCH COLLABORATIONS
  • CLINICAL TRIALS

CHAPTER 9 THE LIMITATIONS OF BIOBANKS

  • SAMPLE VARIABILITY
  • SAMPLE QUALITY
  • EFFORTS TO INCREASE HARMONIZATION
  • INITIATIVES TO IMPROVE BIOBANKS

CHAPTER 10 REGULATORY DYNAMICS, INTELLECTUAL PROPERTY, ETHICAL CONSIDERATIONS

  • INTRODUCTION
  • ROLE OF THE FOOD & DRUG ADMINISTRATION
  • CURRENT REGULATORY FRAMEWORK
  • INFORMED CONSENT
  • WITHDRAWAL AND OWNERSHIP
  • CONFIDENTIALITY
  • COMMERCIALIZATION
  • FDA GUIDELINES FOR BIOMARKER APPLICATIONS
  • TABLE 25 FDA GUIDELINES FOR BIOMARKER APPLICATIONS
  • EUROPEAN MEDICINES AGENCY
    • REGULATORY IMPACT ON DRUG SAFETY
  • INTELLECTUAL PROPERTY AND COMPETITIVE POSITIONING
    • APPROVED PATENT ANALYSIS
    • TABLE 26 GLOBAL ANNUAL PATENTS FILED AND APPROVED WITH BIOMARKER CLAIMS BY REGION, THROUGH 2016
    • COMPETITIVE LANDSCAPE
    • LATE STAGE CLINICAL TRIALS: COMPETITIVE POSITIONING
    • TABLE 27 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS BY SERVICES AND PRODUCTS, THROUGH 2021 ($ MILLIONS)
    • TABLE 28 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER DELIVERY
    • TABLE 29 REPRESENTATIVE LIST OF APPROVED BIOMARKER PATENTS IN THE U.S., EUROPE AND JAPAN
  • ETHICAL CONSIDERATIONS
    • SUMMARY
  • REGULATORY IMPLICATIONS

CHAPTER 11 BIOBANK MARKETS FORECAST BY SEGMENT AND REGION

  • SUMMARY
  • TABLE 30 GLOBAL MARKET FOR BIOBANKS BY SEGMENT, THROUGH 2021 ($ BILLIONS)
  • GEOGRAPHIC MIX
  • TABLE 31 GLOBAL MARKET SHARE OF BIOBANKS BY REGION, 2015-2021 (%)

CHAPTER 12 DETAILED DESCRIPTION OF THE USE OF BIOMARKERS

  • COLORECTAL CANCER
    • CETUXIMAB
    • PANITUMUMAB
    • ELESCLOMOL
    • HERCEPTIN
  • OTHER PREDICTIVE TESTS
  • TABLE 32 CURRENT ACTIVE BIOMARKER TRIALS ONGOING: ONCOLOGY
  • BREAST CANCER
    • MAMMAPRINT
    • TABLE 33 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: BREAST CANCER, 2007-2009
    • ONCOTYPE DX
  • TEST ADOPTION
    • OTHER PROGNOSTIC TESTS
    • HORMONAL THERAPIES
    • TAXANES/ANTHRACYCLINES
  • TRIPLE NEGATIVE BREAST CANCER
  • OTHER NOVEL BIOMARKERS
  • LUNG CANCER
    • INTRODUCTION
    • PREDICTIVE TESTS
    • TABLE 34 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: LUNG CANCER, 2006-2014
    • GEFITINIB
    • ERLOTINIB
  • OTHER PREDICTIVE TESTS
  • NOVEL THERAPIES
    • PROSTATE CANCER
    • OVARIAN CANCER
    • MALIGNANT MELANOMA
    • TABLE 35 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: MALIGNANT MELANOMA, 2006-2016
  • CARDIOVASCULAR
  • TABLE 36 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CARDIOVASCULAR, 2010-2014
  • CENTRAL NERVOUS SYSTEM
  • TABLE 37 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE, 2010-2013
  • TABLE 38 BIOMARKERS/TEST FOR OTHER NEUROLOGICAL DISEASES, 2008-2009
  • IMMUNOLOGY- AUTOIMMUNE DISEASES
  • TABLE 39 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: IMMUNOLOGY, 2009-2014
  • IMMUNOLOGY
    • BENLYSTA: HUMAN GENOME SCIENCES
    • EXPEDITION AND IDENTITY ALZHEIMER'S TRIAL: ELI LILLY

CHAPTER 13 COMPANY ANALYSIS

  • ABBOTT LABORATORIES INC.
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 40 ABBOTT REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
    • COMPANY STRATEGY
  • AFFYMETRIX, INC.
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • COMPANY STRATEGY
  • ASTERAND PLC
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 41 ASTERAND PRODUCTS OVERVIEW BY TYPE OF BIOBANK
    • COMPANY STRATEGY
  • ASTRAZENECA LTD
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 42 ASTRAZENECA REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
    • COMPANY STRATEGY
  • BAYER SCHERING PHARMA AG
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • COMPANY STRATEGY
  • BIOCHAIN-GENOMICS
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 43 BIOCHAIN-GENOMICS' PRODUCTS OVERVIEW BY TYPE OF BIOBANK
    • COMPANY STRATEGY
  • BIOSTORAGE TECHNOLOGIES, INC.
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 44 BIOSTORAGE TECHNOLOGIES' PRODUCTS OVERVIEW BY TYPE OF BIOBANK
    • COMPANY STRATEGY
  • BOEHRINGER INGELHEIM GMBH
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • COMPANY STRATEGY
  • BRISTOL-MYERS SQUIBB CO
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 45 BMS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
    • COMPANY STRATEGY
  • DAIICHI SANKYO COMPANY, LTD
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • COMPANY STRATEGY
  • ELI LILLY AND COMPANY
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 46 ELI LILLY REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
    • COMPANY STRATEGY
  • EXIQON LIFE SCIENCES
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 47 EXIQON PRODUCTS OVERVIEW BY TYPE OF BIOBANK
    • COMPANY STRATEGY
  • GLAXOSMITHKLINE
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 48 GSK REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
    • COMPANY STRATEGY
  • JOHNSON & JOHNSON LTD
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • COMPANY STRATEGY
  • MILLENNIUM PHARMACEUTICALS
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 49 MILLENNIUM PRODUCTS OVERVIEW BY TYPE OF BIOBANK
    • COMPANY STRATEGY
  • MERCK & CO.
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 50 MERCK REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
    • COMPANY STRATEGY
  • NOVARTIS AG
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 51 NOVARTIS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
    • COMPANY STRATEGY
  • PFIZER INC
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 52 PFIZER REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
    • COMPANY STRATEGY
  • F. HOFFMAN-LA ROCHE AG
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 53 ROCHE REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
    • COMPANY STRATEGY
  • SANOFI-AVENTIS
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 54 SANOFI-AVENTIS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
    • COMPANY STRATEGY
  • SCIPAC
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • TABLE 55 SCIPAC PRODUCTS OVERVIEW BY TYPE OF BIOBANK
    • COMPANY STRATEGY
  • TAKEDA PHARMACEUTICALS LTD
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • COMPANY STRATEGY
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • COMPANY OVERVIEW
    • PRODUCTS AND SERVICES
    • COMPANY STRATEGY

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR BIOBANKS BY SEGMENT, THROUGH 2021 ($ BILLIONS)
  • TABLE 1 CUMULATIVE NUMBER OF DNA SAMPLES BANKED IN POPULATION-BASED STUDIES*, 1970-2015
  • TABLE 2 VALUE OF DNA SAMPLES STORED, THROUGH 2021
  • TABLE 3 NIH SPONSORED CLINICAL TRIALS CONDUCTING GENE EXPRESSION PROFILING, 2000-2014* (CUMULATIVE NUMBER OF NIH -SPONSORED CLINICAL TRIALS)
  • TABLE 4 GLOBAL MARKET FOR BIOBANKING BY APPLICATION, THROUGH 2021 ($ MILLIONS)
  • TABLE 5 SELECTED CANCER BIOBANKS IN THE U.S.
  • TABLE 6 GLOBAL MARKET FOR BIOMARKERS IN LATE STAGE CLINICAL USE BY THERAPEUTIC AREA, THROUGH 2021 ($ MILLIONS/%)
  • TABLE 7 APPLICATION OF BIOBANKS IN CANCER TREATMENT
  • TABLE 8 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: ONCOLOGY
  • TABLE 9 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CARDIOVASCULAR
  • TABLE 10 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE
  • TABLE 11 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: IMMUNOLOGY
  • TABLE 12 GLOBAL MAJOR BIOBANKS LOCATIONS, BY COUNTRY, 1998-2009
  • TABLE 13 TYPES OF BIOBANKS
  • TABLE 14 MAJOR NHLBI COHORT STUDIES
  • TABLE 15 EXAMPLES OF MAJOR DISEASE-BASED BIOBANKS
  • TABLE 16 ESTABLISHMENTS LICENSED TO OPERATE BIOBANKS IN THE U.K., 2016
  • TABLE 17 FUNDING SOURCES FOR BIOBANKS LICENSED IN THE U.K. (%)
  • TABLE 18 COMPOSITE FUNDING METHODS FOR BIOBANKS IN BBMRI COUNTRIES (%)
  • TABLE 19 DISTRIBUTION OF BIOBANKS IN EU COUNTRIES
  • TABLE 20 OWNERSHIP OF EUROPEAN BIOBANKS (%)
  • TABLE 21 ACCESS TO THE EUROPEAN BIOBANK (%)
  • TABLE 22 GROWTH IN DISEASE-BASED BIOBANKS BY THERAPY IN THE U.S., 2007-2014
  • TABLE 23 SELECTED POPULATION-BASED COHORT BIOBANKS, 1976-2009
  • TABLE 24 FOUNDER POPULATION-BASED BIOBANKS
  • TABLE 25 FDA GUIDELINES FOR BIOMARKER APPLICATIONS
  • TABLE 26 GLOBAL ANNUAL PATENTS FILED AND APPROVED WITH BIOMARKER CLAIMS BY REGION, THROUGH 2016
  • TABLE 27 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS BY SERVICES AND PRODUCTS, THROUGH 2021 ($ MILLIONS)
  • TABLE 28 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER DELIVERY
  • TABLE 29 REPRESENTATIVE LIST OF APPROVED BIOMARKER PATENTS IN THE U.S., EUROPE AND JAPAN
  • TABLE 30 GLOBAL MARKET FOR BIOBANKS BY SEGMENT, THROUGH 2021 ($ BILLIONS)
  • TABLE 31 GLOBAL MARKET SHARE OF BIOBANKS BY REGION, 2015-2021 (%)
  • TABLE 32 CURRENT ACTIVE BIOMARKER TRIALS ONGOING: ONCOLOGY
  • TABLE 33 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: BREAST CANCER, 2007-2009
  • TABLE 34 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: LUNG CANCER, 2006-2014
  • TABLE 35 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: MALIGNANT MELANOMA, 2006-2016
  • TABLE 36 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CARDIOVASCULAR, 2010-2014
  • TABLE 37 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE, 2010-2013
  • TABLE 38 BIOMARKERS/TEST FOR OTHER NEUROLOGICAL DISEASES, 2008-2009
  • TABLE 39 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: IMMUNOLOGY, 2009-2014
  • TABLE 40 ABBOTT REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
  • TABLE 41 ASTERAND PRODUCTS OVERVIEW BY TYPE OF BIOBANK
  • TABLE 42 ASTRAZENECA REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
  • TABLE 43 BIOCHAIN-GENOMICS' PRODUCTS OVERVIEW BY TYPE OF BIOBANK
  • TABLE 44 BIOSTORAGE TECHNOLOGIES' PRODUCTS OVERVIEW BY TYPE OF BIOBANK
  • TABLE 45 BMS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
  • TABLE 46 ELI LILLY REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
  • TABLE 47 EXIQON PRODUCTS OVERVIEW BY TYPE OF BIOBANK
  • TABLE 48 GSK REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
  • TABLE 49 MILLENNIUM PRODUCTS OVERVIEW BY TYPE OF BIOBANK
  • TABLE 50 MERCK REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
  • TABLE 51 NOVARTIS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
  • TABLE 52 PFIZER REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
  • TABLE 53 ROCHE REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
  • TABLE 54 SANOFI-AVENTIS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS
  • TABLE 55 SCIPAC PRODUCTS OVERVIEW BY TYPE OF BIOBANK

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR BIOBANKS BY SEGMENT, 2015-2021 ($ BILLIONS)
Back to Top